Fourth Circuit· 10/18/1993

Mylan Laboratories, Inc. v. Matkari

Citations

7 F.3d 1130
1993 WL 411674

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

holding that the plaintiff’s “claims that the defendants falsely represented that their drugs had been ‘properly approved by the FDA’ must fail”
“In considering a motion to dismiss, the court favorable to the plaintiff.”
“Congress did not draft the federal limitations period to 8 begin running only at the end of a particular state’s exhaustion process. Instead, the 9 statute is clear that the limitations period starts from the latest of four specific dates.”
claim that the act of placing a drug on the market with package inserts often used for FDA-approved drugs falsely implies that the drug has received FDA approval, in the absence of a specific statement reflecting ‘FDA approval,’ is ‘too great a stretch under the Lanham Act’

Source: CourtListener parenthetical corpus (CC0).

Judges: Ervin, Murnaghan, Niemeyer, Published, Wrote

Read full opinion on CourtListener

Cited by

104 cases in this archive cite this case; the 20 most cited are listed.

Cites

12 cases in this archive are cited by this case.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.